IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, will participate in a fireside chat at...
Achieves first quarter revenue growth of 14% as reported and 11% organic, and CAG Diagnostics recurring revenue growth of 14% as reported and 11% organic. ...
Barchart Research What to Expect from IDXX Earnings IDXX Generated May 4, 2026 Current Price $563.12 EPS Estimate $$3.42 Consensus Rating Moderate Buy Average Move 10.62% IDEXX Laboratories Set to Reveal...
/Idexx%20Laboratories%2C%20Inc_%20outside%20lab-by%20Sundry%20Photography%20via%20iStock.jpg)
IDEXX Laboratories is ready to release its fiscal first-quarter earnings next month, and analysts project a double-digit profit growth.
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 first quarter financial results for Tuesday, May 5, 2026, before the...
Helping clinicians investigate sooner and plan next steps with confidence
/Idexx%20Laboratories%2C%20Inc_%20phone%20and%20logo-%20by%20T_Schneider%20via%20Shutterstock.jpg)
Despite outperforming the broader S&P 500 Index over the past year, analysts maintain a cautiously optimistic outlook on IDEXX Laboratories’ future prospects.
/Thermo%20Fisher%20Scientific%20Inc_%20site%20magnified-by%20Casimiro%20PT%20via%20Shutterstock.jpg)
Although Thermo Fisher Scientific stock has declined over the past year, it has slightly outperformed other medical device stocks, and analysts remain highly bullish about its prospects.
IDEXX Laboratories has outperformed the broader market over the past year, and analysts remain moderately bullish about the stock’s prospects.